1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Blueprint Still Confident In CDK2 Inhibitor Despite Partial Hold On Phase I/II Trial

 
• By Alaric DeArment

The FDA placed a partial hold on the VELA study of BLU-222 due to some patients experiencing visual toxicity, but the company anticipates reporting data and said it is near identifying Phase II dose.

Blueprint said the FDA placed a partial hold on its Phase I/II CDK2 inhibitor trial • Source: Shutterstock

Blueprint Medicines Corporation’s move into the competitive CDK2 inhibitor space has hit an obstacle as the US Food and Drug Administration has slapped a partial clinical hold on its Phase I/II VELA trial of BLU-222 due to some patients experiencing visual adverse events. But the company anticipates resolving the hold and remains on track to present dose-escalation data in the first half of 2023.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

 
• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from R&D

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

Veraxa Takes SPAC Route To Develop Bispecific ADCs and T-Cell Engagers

 
• By Andrew McConaghie

The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.